The Origin and Clinical Benefit of First-in-Class Drugs that entered the French market between 2008 and 2018

Osipenko, L. (2023). The Origin and Clinical Benefit of First-in-Class Drugs that entered the French market between 2008 and 2018. [Dataset]. Zenodo. https://doi.org/10.5281/zenodo.7823469
Copy

This file contains a data set of 135 First-in-class medicines that entered the French market between 2008 to 2018. For each drug we present data on provenance (inventor of the drug) and clinical benefit grading by Haute Autorité de Santé (HAS) and Prescrire. A legend on matching clinical grading scale can be found on tab 3 of the document.
Item Type Dataset
Publisher Zenodo
DOI 10.5281/zenodo.7823469
Date made available 12 April 2023
Keywords fist-in-class medicines, France, haute autorite de sante, clinical benefit grading, Prescrire
Temporal coverage
From
To
2008
2018
Geographic coverage France
Resource language Other
Departments LSE

Explore Further

Available at: 10.5281/zenodo.7823469

Access level: Open

Licence: Creative Commons: Attribution 4.0


Export as

EndNote BibTeX Reference Manager Refer Atom Dublin Core JSON Multiline CSV
Export

Downloads